<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe a 42-year-old male who was in good health until he presented with a high grade B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> that had both MYC and t(14;18) translocations </plain></SENT>
<SENT sid="1" pm="."><plain>This process has now been classified as "B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassifiable, with features intermediate between diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>," according to the 2008 World Health Organization Classification of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumours</z:e> of Haematopoitic and Lymphoid Tissues </plain></SENT>
<SENT sid="2" pm="."><plain>The clinical presentation, pathologic work-up including examination of the peripheral blood, lymph node biopsy, bone marrow <z:hpo ids='HP_0002835'>aspiration</z:hpo> and biopsy are included </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment consisted of seven cycles of chemotherapy following the CALGB protocol 9251 </plain></SENT>
<SENT sid="4" pm="."><plain>Prognosis is generally reported as poor in these aggressive "double-hit" <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>However, this patient's disease has now been in remission for two years </plain></SENT>
</text></document>